Open official notice

Daisho Pharmaceutical “Haiseifu S Granules” - Recall

Official notice

16 Feb 2026

Last checked

27 Oct 2026

RecallScope risk estimate:MediumCAA Japan

An official CAA Japan notice concerns Daisho Pharmaceutical “Haiseifu S Granules” - Recall. The measured chlorpheniramine maleate content was found to exceed the upper specification limit. Recall reason: Stability monitoring after 1 year found that the measured chlorpheniramine maleate content exceeded the upper specification limit, so we decided to voluntarily recall the affected lots. Specific potential health effects: Although the content of the active ingredient chlorpheniramine maleate exceeds the upper specification limit, it is at or below the upper limit under the approval standards for oral medicines, and serious adverse health effects are considered unlikely. No adverse health effects related to this issue have been reported to date. Published 2026-02-16.

What to do now

All shipment destinations for the product are known. We will notify them in writing of the recall and promptly recall the product.

Recall number

2-12683

Official notice

2026-02-16

The hazard

The measured chlorpheniramine maleate content was found to exceed the upper specification limit. Recall reason: Stability monitoring after 1 year found that the measured chlorpheniramine maleate content exceeded the upper specification limit, so we decided to voluntarily recall the affected lots. Specific potential health effects: Although the content of the active ingredient chlorpheniramine maleate exceeds the upper specification limit, it is at or below the upper limit under the approval standards for oral medicines, and serious adverse health effects are considered unlikely. No adverse health effects related to this issue have been reported to date.

How to check if you're affected

Compare the product name and identifiers below with the item you own. Check the official notice for the affected products and next steps.

Recall Numbers

2-12683

Checked manually this time?

Follow brands and keywords in the app to receive alerts for matching official notices.

Turn on recall alerts

Affected products

Product 1

ハイセーフーS顆粒

Hazard

The measured chlorpheniramine maleate content was found to exceed the upper specification limit. Recall reason: Stability monitoring after 1 year found that the measured chlorpheniramine maleate content exceeded the upper specification limit, so we decided to voluntarily recall the affected lots. Specific potential health effects: Although the content of the active ingredient chlorpheniramine maleate exceeds the upper specification limit, it is at or below the upper limit under the approval standards for oral medicines, and serious adverse health effects are considered unlikely. No adverse health effects related to this issue have been reported to date.

Where it was sold

Retailer information is not currently available in RecallScope. Check the official notice for distribution details.

Location 1

JP · Japan

Affected area 1

JP · Japan

Company & contacts

Brand

大昭製薬

Manufacturer

大昭製薬株式会社

Phone

0748-88-4181

Brand: 大昭製薬. Contact: 大昭製薬株式会社. Phone 0748-88-4181.

Source & status

Source

Tier

official

Category

HEALTH

Official classification

PMDA Class II — 回収

Recall details

Recall number

2-12683

Event id

CAA-00000034933

Source tier

official

Documents, notices & source

See the official notice and source documents for full details.

View full official notice
Something wrong on this page?

Weekly recall digest

Get next week's recalls before you need them.

One email every Monday — official-source recalls for your country, and nothing else. Unsubscribe from any email.

The digest arrives once a week. For matching recall alerts after notices are processed, get the app.

This recall was published 16 Feb 2026. The next one won't wait for you to search.

RecallScope checks listed publishers for the brands and VINs you follow, and can alert you when a matching notice is processed.

apple-buttongoogle-button